Alectinib demonstrated potent antitumor activity in both in vitro and in vivo models against tumor cell lines harboring ALK gene alterations, including NSCLC cells with the EML4-ALK fusion. The gene discussed is EML4; the disease is non-small cell lung carcinoma.